GSK3B and myocardial infarction: We previously showed that pretreatment with a weight-reducing dose of a glucagon-like peptide-1 (GLP-1) agonist, liraglutide is associated with activation of Akt/GSK3β axis, reduction of cardiac rupture post-MI and improved survival with no effect on infarct size at 2d post MI [25].